#None #Class Action #Stockholder Rights #Novo Nordisk

Attention Novo Nordisk Shareholders

Robbins LLP, a leading firm in shareholder rights litigation, has released an important reminder for investors who purchased stocks of Novo Nordisk A/S (NYSE: NVO) during a specific period. Investors are encouraged to participate in a class action lawsuit filed against the company for potential misleading statements that may have impacted its stock value.

Overview of the Allegations

The class action lawsuit focuses on assertions made by Novo Nordisk between May 7, 2025, and July 28, 2025. Allegations include claims that the company inflated its revenue and profit growth projections, creating an overly optimistic picture of its future in the highly competitive pharmaceutical market. Specific concerns are outlined in the legal document, which states that:

1. Overstated Growth Potential: The company is accused of misrepresenting its growth agenda, failing to adequately incorporate impacts from the personalization exception related to compounded GLP-1 drugs.
2. Misleading Market Transition Projections: It's alleged that Novo Nordisk misrepresented the extent to which patients would move from compounded GLP-1 treatments to their branded products.
3. Inflated Market Size Claims: The complaint further suggests that Novo Nordisk exaggerated both the actual size of the GLP-1 market and the company's anticipated capacity to gain market share to sustain growth levels.

On July 29, 2025, following the announcement that the firm would lower its sales forecast amid failing product demand and heightened competition, the stock price of Novo Nordisk plummeted from $69 to $53.94. This drop in stock value has significant implications for investors who may have been misled by previous claims made by the company.

Next Steps for Shareholders

In light of these events, shareholders who wish to take a more active role in this lawsuit are encouraged to consider being named as lead plaintiffs. Those interested must submit their court documents by September 30, 2025. Being a lead plaintiff grants investors the authority to guide the litigation process for all affected shareholders.

It’s important to note that participating as a lead plaintiff is not a requirement to recover potential losses. Shareholders can remain absent class members if they prefer. All legal representation throughout this lawsuit is contingent upon winning, meaning investors do not face upfront costs.

About Robbins LLP

Since its establishment in 2002, Robbins LLP has gained recognition for dedication to protecting shareholder rights and assisting in recovering losses. The firm prioritizes accountability in corporate governance and helps ensure company executives answer for their actions. Investors interested in staying updated about this ongoing lawsuit are encouraged to sign up for Stock Watch notifications, which will inform them once there's news on settlements or related corporate misconduct.

For additional details or inquiries, interested parties can reach out via:

• - Email: attorney Aaron Dumas, Jr.
• - Phone: (800) 350-6003

This avenue not only serves to inform the class members but also prepares them to take appropriate steps toward safeguarding their investments.